Monday, October 6, 2025

Latest

MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the first patient has been dosed in a Phase 1 investigator-initiated study aimed to evaluate the effects of MDMA-like substances. The study is being led by the firm’s collaborator and the program’s principal investigator, Dr. Matthias Liechti at University Hospital Basel.

The trial involves 24 healthy subjects who will randomly receive doses of MDMA or MDMA-like substances like MDA, Lys-MDMA, and Lys-MDA, while the rest will get placebo treatments. The study aims to assess the subjective effects of the various drugs for future application of the substance in treating disorders.

“By using pharmacokinetics and modern psychological and psychometric tests, this study will investigate the potential to better control the bioavailability, slow the effect onset and reduce possible adverse effects of MDMA and MDA by using these prodrugs,” said Dr. Liechti.

The principal investigator also said the study will investigate the “effects of MDA in direct comparison with MDMA for the first time in humans.”

Executive President Dr. Miri Halperin Wernli added that the study “will enhance our understanding of the therapeutic properties involved in the induction of positive mood in a way that may help optimize the treatment model for our R(-)-MDMA drug candidate.”

The firm started in October 2021 to develop R(-)-MDMA for treating symptoms related to autism spectrum disorder.

Mind Medicine Inc. last traded at $9.35 on the NEO.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM

Champignon Brands Vs Mind Medicine: A Comparison

Champignon Brands (CSE: SHRM), prior to the public listing of the company, had a primary...

Monday, April 20, 2020, 09:01:13 AM

Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant

Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get...

Thursday, August 25, 2022, 08:50:31 AM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM

JR Rahn: Using LSD To Treat Mental Health – The Daily Dive

For our Saturday edition of The Daily Dive, host Cassandra Leah sits down with that...

Saturday, March 20, 2021, 01:30:00 PM